Physician profile
Elyse Huff
NPI 1093213688
$8,334.44
in general payments reported to CMS, 2019-2025
60 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,926 · 2024: $2,634 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,490 · Education: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,490.47 |
| Education | $843.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,733.50 | 2023-2025 | |
| Incyte Corporation | $554.14 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $425.14 | 2023-2025 | Lynparza, Enhertu, Imfinzi |
| Pfizer INC. | $418.78 | 2023-2025 | |
| Astellas Pharma US INC | $392.60 | 2023-2024 | Xtandi |
| Seagen INC. | $366.83 | 2023-2025 | Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $346.15 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $329.21 | 2023-2025 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $315.65 | 2023-2025 | Injectafer, Enhertu, Vanflyta |
| Janssen Biotech, INC. | $253.37 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Beigene USA, INC. | $227.37 | 2023-2024 | Brukinsa |
| Celgene Corporation | $216.62 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Genzyme Corporation | $209.03 | 2023-2025 | |
| Lilly USA, LLC | $191.92 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $162.11 | 2023-2025 | Lorbrena, Braftovi |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $145.02 | 2023-2025 | Ninlaro, Alunbrig, Iclusig |
| Stemline Therapeutics INC. | $117.81 | 2023-2025 | Orserdu |
| Eisai INC. | $117.45 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.10 | 2023-2025 | |
| Beone Medicines USA, INC. | $92.07 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $83.66 | 2023-2025 | Libtayo, Lynozyfic |
| Pharmacosmos Therapeutics INC. | $83.10 | 2023-2024 | Monoferric, Cosela |
| Jazz Pharmaceuticals INC. | $80.26 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $77.81 | 2023-2025 | Xpovio |
| Gilead Sciences, INC. | $72.29 | 2023-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $70.54 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $68.48 | 2024-2025 | Pyrukynd |
| Caris Mpi, INC. | $67.47 | 2025 | Mi Cancer Seek |
| Sobi, INC | $65.59 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $65.28 | 2024-2025 | Opdivo |
| Genentech USA, INC. | $62.74 | 2024-2025 | Venclexta, Alecensa, Tecentriq |
| Mirati Therapeutics, INC. | $62.00 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $52.84 | 2023 | Tazverik, Onivyde, Somatuline Depot |
| Dendreon Pharmaceuticals LLC | $50.36 | 2025 | Provenge |
| Adc Therapeutics America, INC. | $43.83 | 2024-2025 | |
| Pharmaessentia USA Corporation | $43.66 | 2024-2025 | Besremi |
| Amgen INC. | $43.07 | 2023 | Kyprolis, Blincyto |
| Myriad Genetic Laboratories, INC. | $40.88 | 2023-2024 | Myrisk |
| Pharmacyclics LLC, An Abbvie Company | $39.76 | 2023 | Imbruvica, Epkinly |
| Tersera Therapeutics LLC | $36.29 | 2023-2024 | Zoladex |
| Amneal Pharmaceuticals LLC | $29.98 | 2023-2024 | Neulasta, Neupogen, Avastin |
| Merz North America, INC. | $28.09 | 2025 | |
| Genmab U.S., INC. | $24.40 | 2024 | Epkinly |
| Legend Biotech USA INC. | $23.11 | 2025 | Carvykti |
| Emd Serono, INC. | $22.86 | 2024 | |
| Spectrum Pharmaceuticals INC. | $21.51 | 2024 | Rolvedon |
| Blueprint Medicines Corporation | $21.05 | 2023 | Ayvakit |
| Acrotech Biopharma INC. | $20.90 | 2024 | Ryzneuta |
| Glaxosmithkline, LLC. | $19.05 | 2024 | Zejula, Jemperli |
| Deciphera Pharmaceuticals INC. | $18.98 | 2023 | Qinlock |
| Macrogenics, INC. | $18.94 | 2023 | |
| Aveo Pharmaceuticals, INC. | $18.41 | 2023 | Fotivda |
| Apellis Pharmaceuticals, INC. | $17.84 | 2023 | Empaveli |
| Springworks Therapeutics, INC. | $17.72 | 2024 | Ogsiveo |
| Mylan Institutional INC. | $17.54 | 2023 | Ogivri, Fulphila |
| Foundation Medicine, INC. | $17.26 | 2023 | |
| Tolmar, INC. | $16.92 | 2024 | |
| G1 Therapeutics, INC. | $16.64 | 2023 | Cosela |
| Taiho Oncology, INC. | $16.62 | 2024 | |
| Geron Corporation | $15.84 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.